New Treatments for Sickle Cell Disease

Imaging advances and systemic therapies are redefining care for sickle cell retinopathy.

By Jason Dossantos, BS, Mirataollah Salabati, MD, Jessica D. Randolph, MD

Gene Therapies for Inherited Retinal Diseases

Augmentation, RNA editing, and gene-agnostic approaches offer hope for patients with RP, Stargardt disease, LCA, and XLRS.

By Christine Nichols Kay, MD

Novel Therapies for Stargardt Disease

Both gene-targeted and gene-agnostic treatments have been shown to restore ABCA4 function and impact broader retinal processes.

By Cesar Estrada-Puente, MD, Paula C. Morales, MD, Ramiro S. Maldonado, MD

Counseling Patients About Gene Therapy

Tips for setting realistic expectations about eligibility, outcomes, and treatment barriers.

By Kari Branham, MS, CGC, Michelle Alabek, MS, CGC, Dana Schlegel, MS, MPH, CGC

Navigating MacTel From Diagnosis to Therapy

Encelto offers new hope to patients, but optimizing this therapy will depend on early recognition of the disease along with informed counseling.

By David A. Eichenbaum, MD

Navigating Optogenetics in the IRD Pipeline

This type of gene therapy offers a mutation-agnostic and disease-agnostic approach for patients with advanced retinal disease.

By Kenneth C. Fan, MD, MBA

Looking Forward to AAO

Upfront: This issue features articles on inherited retinal diseases and gene therapy.

By Diana V. Do, MD

Avoiding Billing and Documentation Pitfalls in IRD Coding

Coding: What retina practices need to know about billing for inherited retinal diseases and upcoming genetic treatments.

By Elizabeth Cifers, MBA, MSW, CHC, CPC

Clinical Trial Update October 2025

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.